Asia Pacific Chronic Cough Market

Market Introduction

Chronic cough is defined as a persistent cough that lasts long up to 6-8 weeks. It significantly affects the patients' lives by interrupting sleeping, vomiting, light-headedness, and even rib fractures. It is caused due to multiple reasons such as infections, asthma, gastroesophageal reflux disease (GERD), among others.

Market Overview and Dynamics

The Asia Pacific Chronic Cough marketis expected to grow from US$  1,136.66 million in 2019 to US$  2,155.25 million by 2027. This represents a CAGR of 8.4% from 2020 to 2027. The growth of the Asia Pacific Chronic Cough market is attributed to the Rising Incidences of chronic cough, growing product developments to treat chronic cough. However, the product recallslimits the growth of market in this region. Countries in Asia Pacific are expecting to witness huge challenge due to growing COVID-19. Due to outbreak of disease, healthcare industries has been affected badly. Due to growing coronavirus cases, many business related activities such as product launches and product promotion conferences has been postponed, leading to restraining the growth of the market.

Key Market Segments

Based on drug class, the Asia Pacific Chronic Cough market is segmented into antihistamines, corticosteroids, decongestants, combination drug, antibiotics, acid blockers, and other drug class. In 2019, the combination drug segment held a larger share of the market and is expected to grow at a faster rate during the forecast period.

Major Sources and Companies Listed

A few major primary and secondary sources referred towhile preparing the Asia Pacific Chronic Cough Marketreport are World Health Organization, Ministry Of Health And Family Welfare, and Australian Therapeutic Goods Administration.Novartis AG, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc., Bayer AG, Mylan N.V., Amneal Pharmaceuticals, Inc., Cipla Inc., Reckitt Benckiser Group plc., Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd.

Reasons to buy the report

• To understand the Asia Pacific Chronic Cough marketlandscape and identifymarket segments that are most likely to guarantee a strong return
• To stay ahead incomprehending the ever-changing competitive landscape of theAsia Pacific Chronic Cough market
• To efficiently plan M&A and partnership dealsin the Asia Pacific Chronic Cough marketby identifying market segments with the most promising probable sales
• To help takeknowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segmentsinthe Asia Pacific Chronic Cough market
• To obtain market revenue forecast from 2019 to 2027 in various segmentsofthe Asia Pacific Chronic Cough market

ASIA PACIFIC CHRONIC COUGH MARKETSEGMENTATION

By Drug Class

·      Antihistamines

·      Corticosteroids

·      Decongestants

·      Combination Drug

·      Antibiotics

·      Acid Blockers

·      Other Drug Class

By Route of Administration

·      Oral

·      Injections

·      Nasal

·      Other Route of Administration

By Distribution Channel

·      Hospital Pharmacy

·      Online Pharmacy

·      Retail Pharmacy

By Country

·      Japan

·      China

·      India

·      South Korea

·      Australia

Company Profiles

• Novartis AG
• Teva Pharmaceutical Industries Ltd
• GlaxoSmithKline plc.
• Bayer AG
• Mylan N.V.
• Amneal Pharmaceuticals, Inc.
• Cipla Inc.
• Reckitt Benckiser Group plc.
• Sun Pharmaceutical Industries Ltd

• Aurobindo Pharma Ltd.

Asia Pacific Chronic Cough Market Strategic Insights

Asia Pacific Chronic Cough Market Segmentation Analysis

Asia Pacific Chronic Cough Market Report Highlights

Asia Pacific Chronic Cough Report Scope

Asia Pacific Chronic Cough Market Country and Regional Insights